EP1963306A2 - Esomeprazol-arginin - Google Patents

Esomeprazol-arginin

Info

Publication number
EP1963306A2
EP1963306A2 EP06841138A EP06841138A EP1963306A2 EP 1963306 A2 EP1963306 A2 EP 1963306A2 EP 06841138 A EP06841138 A EP 06841138A EP 06841138 A EP06841138 A EP 06841138A EP 1963306 A2 EP1963306 A2 EP 1963306A2
Authority
EP
European Patent Office
Prior art keywords
esomeprazole
arginine
layer
pellets
tablets
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP06841138A
Other languages
English (en)
French (fr)
Inventor
Berta Kotar-Jordan
Robert Pisek
Natalija Zajc
Anamarija Vajs
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KRKA dd
Original Assignee
KRKA Tovarna Zdravil dd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by KRKA Tovarna Zdravil dd filed Critical KRKA Tovarna Zdravil dd
Priority to EP06841138A priority Critical patent/EP1963306A2/de
Publication of EP1963306A2 publication Critical patent/EP1963306A2/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Definitions

  • the present invention relates to esomeprazole arginine as well as processes for its preparation and pharmaceutical compositions containing it.
  • Esomeprazole is the (S) (-) enantiomer of omeprazole, a sulfoxide which has an asymmetric center at the sulfur atom and exists in form of different enantiomers.
  • the chemical name of omeprazole is 5-methoxy-2- [ [ (4-methoxy-3, 5-dimethyl-2-pyridi- nyl) -methyl] sulphinyl] -lH-benzimidazole .
  • Omeprazole is in-vivo transformed into an effective inhibitor of gastric acid secretion and is therefore useful as an anti-ulcer agent or for preventing and/or treating gastric acid related disorders and gastrointestinal inflammatory diseases in mammals.
  • omeprazole may be used to prevent and/or treat gastritis, gastric ulcer and duodenal ulcer.
  • Omeprazole, and its therapeutically acceptable alkaline salts are disclosed in EP 5 129 and EP 124 95, respectively.
  • DE 4035455 discloses the separation of the enantiomers of omeprazole using a diastereomeric ether.
  • WO 94/27988 discloses certain salts, namely Na+, Mg2+, Li+, K+, Ca2+ and N(R) 4 + salts, wherein R is an alkyl with 1-4 carbon atoms, of the single enantiomers of omeprazole and their preparation. These compounds are said to have improved pharmacokinetic properties which give an improved therapeutic profile, such as a lower degree of variation between individuals taking the compound.
  • WO 98/54171 describes magnesium esomeprazole trihydrate
  • WO 00/44744 describes specific polymorphs of the potassium salt of esomeprazole
  • WO 2003/74514 discloses some primary amine salts of esomeprazole
  • WO 2004/037253 describes certain alkali metal or amine salts of esomeprazole
  • WO 2004/99182 and WO 2004/99181 disclose zinc and barium salts of esomeprazole, respectively
  • WO2005023796 discloses adamantan ammonium salts of omeprazole and esomeprazole
  • WO2005023797 describes the 1-cyclohexyl ethyl ammonium salt of inter alia esomeprazole.
  • EP 1 018 340 describes amino acid salts compounds of benzimidazole derivatives and their inclusion complexes with cyclodextrins.
  • the amorphous L-arginine omeprazole salt is described which is produced by spray drying.
  • esomeprazole arginine salt is described.
  • the present invention meets this need by providing the esomeprazole arginine according to claims 1 to 5 and 17.
  • the invention also relates to the process for preparing it according to claims 6 to 9 and pharmaceutical compositions comprising the esomeprazole arginine according to claims 10 to 15, in particular the multiple-unit tablets of claim 16.
  • the invention provides esomeprazole arginine which is the product of the chemical reaction between esomeprazole and arginine.
  • This esomeprazole arginine is preferably esomeprazole arginine salt. This is a salt of the know drug esomeprazole with the amino acid arginine and could also be referred to as arginine esomeprazole salt.
  • the esomeprazole arginine shows a very high stability and is therefore very suitable to be included in pharmaceutical compositions.
  • the molar ratio between esomeprazole and arginine is about 1:1 and that arginine is L-arginine.
  • the esomeprazole arginine can be in crystalline form or in amorphous form and the latter form may facilitate its processing into pharmaceutical compositions.
  • the esomeprazole arginine has been characterized by its FT-IR spectrum, X-ray powder diffraction pattern and 1 H-NMR spectrum and analysed in accordance with the article »Enantioselective Analysis of Omeprazole in Pharmaceutical Formulations by Chiral High-Performance Liquid Chromatography and Capillary Electrophoresis « (J. Braz. Chem. Soc, Vol. 15, No. 2, 318-323, 2004) .
  • FT-IR spectra of KBr discs including the esomeprazole arginine according to the invention were recorded over a wave number range of 4000 - 400 cm “1 on a Perkin Elmer Spectrum GX FT-IR spectrometer at a resolution of 4 cm "1 .
  • X-ray powder diffraction patterns were obtained by using a Phillips PW3040/60 ' X' Pert PRO powder diffractometer; CuKa radiation 1.541874A, 3° ⁇ 2 ⁇ 31°.
  • the 1 H-NMR spectrum has been recorded by means of a Varian UNITY+ 300 spectrometer at 300 MHz using DMSO-d ⁇ and tetramethyl silane as internal standard.
  • Figure 1 shows the X-ray powder diffractogram and Figure 2 the FT-IR spectrum of amorphous esomeprazole arginine.
  • Figure 4 shows the particle size distribution of esomeprazole arginine before milling.
  • Figure 5 shows the particle size distribution of esomeprazole arginine after milling.
  • the esomeprazole arginine according to the invention is preferably prepared by a process, wherein esomeprazole and arginine are reacted in a solvent and the solvent is removed.
  • the solvent is in particular selected from water, an alcohol or a mixture thereof.
  • the preferred alcohol is methanol, ethanol, 2-propanol, n-propanol or butanol.
  • the process is carried out until all esomeprazole was dissolved or the pH value of the reaction mixture remained constant.
  • the molar ratio between the esomeprazole and the arginine can vary, but is preferably about 1:1.
  • esomeprazole is dissolved in the selected solvent and then arginine is added. After completion of the reaction the solvent is removed by for example distillation, distillation under vacuum, evaporation, spray drying, and freeze drying.
  • the esomeprazole arginine prepared according to the present invention can have a purity level of up to 99.9%.
  • the esomeprazole used in the process according to the invention can be prepared according to any desired method, many of which are known to those of ordinary skill in the art.
  • suitable methods to manufacture esomeprazole are given by EP 5 129, EP 124 495, EP 533 752, DE 40 35 455, EP 652 872, EP 707 580, EP 773 940, EP 795 024, EP 836 601, EP 897 386, EP 946 547, EP 984 957, EP 964 859, EP 1 004 305, EP 1 095 037, EP 1 104 417, EP 1 230 237, EP 1 409 478, EP 1 458 709, WO 03/08940, EP 1 375 497, WO 2004/2982, WO 2004/52882, WO 2004/87702, EP 1 375 497, WO 2005/54228, and WO 2005/116011.
  • the invention also relates to pharmaceutical compositions which comprise the esomeprazole arginine, preferably esomeprazole arginine salt according to the invention. These compositions may be used for the treatment of gastric-acid related diseases by inhibition of gastric acid secretion.
  • the particle size of the esomeprazole arginine according to present invention is preferably in the range of 0.1-250 microns. If smaller particles are needed, they can be milled or micronized optionally together with other excipients. During this process the mechanical force on the particle surface leads to a particle size reduction. However, it can also release the structure changes of the material.
  • an air jet mill, a ball mill or a hammer mill are commonly used as milling equipment.
  • the basic principle of the treatment in an air jet mill is collision and attrition between particles suspended within a high velocity air stream, which introduces the power to the milling chamber.
  • the particles are fractured by impact of grinding media (e.g. balls, cubes, cylinders, etc.) that can occupy up to half of the mill chamber volume.
  • grinding media e.g. balls, cubes, cylinders, etc.
  • Friction is also present among all elements, contributing significantly to the attrition and consequently to an amorphous nature of the material obtained by the milling.
  • hammer mill One of the most widely used mills in the pharmaceutical industry is the hammer mill. In such an equipment particles are exposed to impact of rapidly rotating hammers. During the milling material additionally hits the perforated screen that is placed over the chamber outlet.
  • compositions according to the invention are preferably in the form of pellets or tablets, in particular those which have an enteric coating layer.
  • the pellets can be filled into hard gelatine capsules or sachets which hence also represent preferred embodiments of the composition.
  • the tables can be prepared from the pellets or from a powder mixture.
  • the pellets preferably comprise (a) a core including the esomeprazole arginine according to the invention,
  • the tablets preferably comprise
  • a core including the esomeprazole arginine according to the invention (b) optionally at least one separating layer, and (c) at least one enteric layer.
  • the pellets and the tablets the esomeprazole arginine is included in the core in form of a layer covering the core.
  • composition comprises zinc hydroxide or zinc carbonate or zinc hydroxide carbonate.
  • the invention also relates to multiple-unit tablets which are obtainable by compressing a mixture of the pellets with tablet excipients .
  • Preferred pellets comprises a pellet core, optionally a separating coating, an enteric coating and optionally an overcoating as follows.
  • the core is prepared from powders comprising esomeprazole arginine and at least one pharmaceutically acceptable excipient by extrusion-spheronization or direct pelletization in a high- shear mixer or a rotor granulator.
  • the core can also be formed by applying a layer containing esomeprazole arginine to an inert bead.
  • the most preferred bead is one prepared from starch and sucrose, even though beads of other pharmaceutically acceptable excipients may be used, such as microcrystalline cellulose, vegetable gums, waxes and the like.
  • the size of the beads may vary between approximately 0.1 and 2 mm.
  • a convenient manner of coating the beads with esomeprazole arginine is the "powder layering" process in centrifugal equipment, i.e. rotor fluid bed equipment (Glatt Rotor Granulator), or a coating pan, i.e. a conventional coating pan
  • the layer with esomeprazole arginine can also be formed in the "suspension layering" or “solution layering” process by spraying the esomeprazole arginine suspension or solution onto the inert cores in a fluid bed coater granulator.
  • Organic solvents or water can be used during this process.
  • the core and in particular the layer with the active ingredient, comprises, besides esomeprazole arginine, at least one excipient selected from stabilizers, fillers, disintegrating agents, wetting agents, binders or other pharmaceutically acceptable ingredients, alone or in mixtures.
  • the stabilizer is preferably chosen among substances, such as sodium, potassium, calcium, magnesium and aluminium salts of phosphoric acid, carbonic acid, citric acid or other suitable weak inorganic or organic acids, aluminium hydroxide/sodium bicarbonate coprecipitate, aluminium, calcium and magnesium hydroxides, magnesium oxide or composite substances, such as Al 2 ⁇ 3 -6MgO-C ⁇ 2 -12H 2 O, (Mg 6 Al 2 (OH) i 6 CO 3 -4H 2 O) , MgO-Al 2 ⁇ 3 -2Si ⁇ 2 -nH 2 O or similar compounds, sodium lauryl sulphate, zinc hydroxide or hydroxide carbonate, alkaline reacting amino acids, their esters and salts or other similar, pharmaceutically acceptable pH- buffering substances.
  • substances such as sodium, potassium, calcium, magnesium and aluminium salts of phosphoric acid, carbonic acid, citric acid or other suitable weak inorganic or organic acids, aluminium hydroxide/sodium bicarbonate coprecip
  • the filler is preferably selected from the group consisting of microcrystalline cellulose, sucrose, starch, lactose, mannitol, sorbitol and mixtures thereof.
  • the disintegrating agent is preferably selected from the group consisting of starch, starch derivatives such as sodium starch glycolate or pregelatinized starch, low-substituted hydroxypro- pyl cellulose, crospovidone, croscarmelose sodium and mixtures thereof.
  • the wetting agent is preferably selected from the group consisting of sodium dodecyl sulphate, polyoxyethylene sorbitan fatty acid esters, poloxamers and mixtures thereof.
  • the binder is preferably selected from the group consisting of polyvinylpyrrolidone, hydroxypropyl cellulose, hydroxypropyl methylcellulose, hydroxyethyl cellulose, methylcellulose and mixtures thereof.
  • said pellets Before applying the enteric coating layer onto the cores present in form of individual pellets, said pellets may optionally be covered with one or more separating layers comprising pharmaceutical excipients optionally including alkaline compounds, such as for instance pH-buffering compounds.
  • This layer/these layers separate (s) the core material from the outer enteric coating layer.
  • the separating layer can be applied to the core by a coating or layering process in a suitable equipment such as a coating pan, coating granulator or in a fluid bed apparatus using water and/or organic solvents for the coating process.
  • the separating layer can be applied to the core by using the powder coating technique.
  • the materials for separating layers are pharmaceutically acceptable compounds, such as sugar, polyethylene glycol, polyvinylpyrrolidone, polyvinyl alcohol, polyvinyl acetate, hydroxypropyl cellulose, methylcellulose, ethylcellulose, hydroxypropyl methylcellulose, carboxymethylcellulose sodium and others, used alone or in mixtures.
  • Additives such as plasticizers, colorants, pigments, fillers, anti-tacking agents and anti-static agents, such as for instance magnesium stearate, titanium dioxide, talc and other additives may also be included in the separating layer.
  • the separating layer may serve as a diffusion barrier and may act as a pH-buffering zone.
  • the pH-buffering properties of the separating layer can be further strengthened by introducing into the layer substances chosen from a group of compounds usually used in antacid formulations, such as magnesium oxide, hydroxide or carbonate, zinc hydroxide or hydroxide carbonate, aluminium or calcium hydroxide, carbonate or silicate, composite aluminium/magnesium compounds, such as Al 2 ⁇ 3 -6MgO-CO 2 -12H 2 ⁇ , (Mg 6 Al 2 (OH) 16 CO 3 -4H 2 O) , MgO-Al 2 O 3 -2SiO 2 -nH 2 O, aluminium hydroxide/so- dium bicarbonate coprecipitates or similar compounds, or other pharmaceutically acceptable pH-buffering compounds, such as the sodium, potassium, calcium, magnesium and aluminium salts of phosphoric, carbonic, citric or other suitable, week, inorganic or organic acids, or suitable organic bases,
  • the optionally applied separating layer is not essential for the compositions according to the invention.
  • the separating layer may improve the chemical stability of the active substance and/or the physical properties of the final dosage form.
  • the separating layer may also protect the enteric coating layer towards cracking during a compaction process.
  • the separating layer preferably contains pharmaceutically acceptable plasticizers to obtain the desired mechanical properties, such as flexibility and hardness.
  • plasticizers are for example triacetin, citric acid esters, phthalic acid esters, dibutyl sebacate, dimethyl polysiloxan, cetyl alcohol, stearyl alcohol, polyethylene glycols, propylenglycole, polysorbates or other plasticizers.
  • the amount of plasticizer is usually 10-50 % by weight of the separating layer forming material.
  • Additives such as dispersants, colorants, pigments, polymers, anti-tacking agent and antifoaming agents may also be included into the separating layer.
  • the maximum thickness of the applied separating layer is normally only limited by processing conditions .
  • enteric coated layers are applied onto the core or onto the core covered with separating layer (s) by using a suitable coating technique.
  • the enteric coating layer material may be dispersed or dissolved in either water or in suitable organic solvents and is preferably comprising a polymer.
  • enteric coating layer polymers one or more, separately or in combination, of the following can be used: solutions or dispersions of methacrylic acid copolymers, cellulose acetate phthalate, hydroxypropyl methylcellulose phthalate, hydroxy- propyl methylcellulose acetate succinate, polyvinyl acetate phthalate, cellulose acetate trimellitate, carboxymethylethyl- cellulose, shellac or other suitable enteric coating layer polymer (s) .
  • the enteric coating layers can also contain pharmaceutically acceptable plasticizers to obtain the desired mechanical properties, such as flexibility and hardness.
  • plasticizers are for example those mentioned above under 2.
  • the amount of plasticizer is optimized for each enteric coating layer formula, in relation to the selected enteric coating layer polymer (s), selected plasticizer (s) and the applied amount of said polymer (s), in such a way that the mechanical properties, i.e. flexibility and hardness of the enteric coating layer (s) are adjusted so that the acid resistance of the pellets covered with enteric coating layer (s) does not decrease significantly during a compression of the pellets into tablets.
  • the amount of plasticizer is usually 10-50 % by weight of the enteric coating layer polymer (s).
  • Additives such as dispersants, colorants, pigments, polymers, anti-tacking agent and antifoaming agents may also be included into the enteric coating layer (s).
  • Other compounds may be added to increase film thickness and to decrease diffusion of acidic gastric juices into the acid susceptible material.
  • the enteric coating layer (s) usually have a thickness of about at least 10 ⁇ m, preferably more than 20 ⁇ m.
  • the maximum thickness of the applied enteric coating layer (s) is normally only limited by processing conditions.
  • the enteric coated pellets can optionally be covered with one or more over-coating layers.
  • the over-coating layer can be applied to the enteric coating layered pellets by coating or layering procedures in a suitable equipment, such as a coating pan, a coating granulator or in a fluidized bed apparatus using water and/or organic solvents for the coating process.
  • the materials for the over-coating layer are chosen among pharmaceutically acceptable compounds, such as sugar, polyethylene glycol, polyvinylpyrrolidone, polyvinyl alcohol, polyvinyl acetate, hydroxypropyl cellulose, methylcellulose, ethylcellulose, hydroxypropyl methylcellulose, microcrystalline cellulose, car- boxymethylcellulose sodium and others, used alone or in mixtures.
  • Additives such as plasticizers, colorants, pigments, fillers, anti-tacking agents and anti-static agents, such as magnesium stearate, titanium dioxide, talc and other additives may also be included into the over-coating layer.
  • the over-coating layer may further prevent potential agglomeration of enteric coating layered pellets and further enhance a subseguent tableting process.
  • the over-coating layer may also protect the enteric coating layer towards cracking during a compaction process.
  • the over-coating layer contains pharmaceutically acceptable plasticizers to obtain the desired mechanical properties, such as flexibility and hardness.
  • plasticizers are for example triacetin, citric acid esters, phthalic acid esters, dibutyl sebacate, dimethyl polysiloxan, cetyl alcohol, stearyl alcohol, polyethylene glycols, propylenglycole, polysorbates or other plasticizers.
  • the amount of plasticizer is usually 10-50 % by weight of the over-coating layer forming material.
  • Additives such as dispersants, colorants, pigments, polymers, anti-tacking agent and antifoaming agents may also be included into the over-coating layer.
  • the maximum thickness of the applied over-coating layer is normally only limited by processing conditions.
  • the pellets according to the invention can be used for the preparation of multiple unit tablets.
  • the enteric coated pellets with or without an over-coating layer are mixed with tablet excipients, such as fillers, binders, disintegrating agents, lubricants and other pharmaceutically acceptable additives, and compressed into tablets.
  • tablet excipients such as fillers, binders, disintegrating agents, lubricants and other pharmaceutically acceptable additives
  • the compressed tablet is optionally covered with a film forming agent to obtain a smooth surface of the tablet and further enhance the stability of the tablet during packaging and transport .
  • the pharmaceutical composition is in form of tablets which comprise a tablet core, optionally a separating coating , and an enteric coating.
  • the tablet cores are prepared from powder mixtures comprising the active substance and at least one pharmaceutically acceptable excipient by using the process of direct compression. Alternatively, said tablet cores can also be formed in the process of wet- or dry-granulation.
  • the tablet cores comprise, besides esomeprazole arginine, at least one excipient selected from stabilizers, fillers, disintegrating agents, wetting agents, binders or other pharmaceutically acceptable ingredients, alone or in mixtures.
  • the stabilizer is preferably chosen among substances such as sodium, potassium, calcium, magnesium and aluminium salts of phosphoric acid, carbonic acid, citric acid or other suitable weak inorganic or organic acids, aluminium hydroxide/sodium bicarbonate coprecipitates, aluminium, calcium and magnesium hydroxides, magnesium oxide or composite substances such as Al 2 ⁇ 3 -6MgOC ⁇ 2 -12H 2 0, (Mg 6 Al 2 (OH) i 6 CO 3 -4H 2 O) , MgO-Al 2 O 3 -2Si ⁇ 2 -nH 2 O or similar compounds, sodium lauryl sulphate, zinc hydroxide or hydroxide carbonate, alkaline reacting amino acids, their esters and salts, or other similar, pharmaceutically acceptable pH- buffering substances.
  • substances such as sodium, potassium, calcium, magnesium and aluminium salts of phosphoric acid, carbonic acid, citric acid or other suitable weak inorganic or organic acids, aluminium hydroxide/sodium bicarbonate coprecipitates, aluminiu
  • the filler is preferably selected from the group consisting of microcrystalline cellulose, sucrose, starch, lactose, mannitol, sorbitol and mixtures thereof.
  • the disintegrating agent is preferably selected from the group consisting of starch, starch derivatives such as sodium starch glycolate or pregelatinized starch, low-substituted hydroxy- propyl cellulose, crospovidone, croscarmelose sodium and mixtures thereof.
  • the wetting agent is preferably selected from the group consisting of sodium dodecyl sulphate, polyoxyethylene sorbitan fatty acid esters, poloxamers and mixtures thereof.
  • the binder is preferably selected from the group consisting of polyvinylpyrrolidone, hydroxypropyl cellulose, hydroxypropyl methylcellulose, hydroxyethyl cellulose, methylcellulose and mixtures thereof.
  • said tablet cores may optionally be covered with one or more separating layers comprising pharmaceutical excipients optionally including alkaline compounds, such as pH-buffering compounds.
  • This layer/these layers separate (s) the core material from the outer enteric coating layer.
  • the separating layer can be applied to the core by a coating or layering process in a suitable equipment, such as a coating pan, a coating granulator or in a fluid bed apparatus using water and/or organic solvents for the coating process.
  • the separating layer can be applied to the tablet core by using a suitable coating technique.
  • the materials for separating layers are pharmaceutically acceptable compounds, such as sugar, poly- ethylene glycol, polyvinylpyrrolidone, polyvinyl alcohol, polyvinyl acetate, hydroxypropyl cellulose, methylcellulose, ethylcellulose, hydroxypropyl methylcellulose, carboxymethyl- cellulose sodium and others, used alone or in mixtures.
  • Additives such as plasticizers, colorants, pigments, fillers, anti-tacking agents and anti-static agents, such as magnesium stearate, titanium dioxide, talc and other additives may also be included into the separating layer.
  • the separating layer may serve as a diffusion barrier and may act as a pH-buffering zone.
  • the pH-buffering properties of the separating layer can be further strengthened by introducing into the layer substances chosen from a group of compounds usually used in antacid formulations, such as magnesium oxide, hydroxide or carbonate, zinc hydroxide or hydroxide carbonate, aluminium or calcium hydroxide, carbonate or silicate, composite aluminium/magnesium compounds, such as Al 2 ⁇ 3 -6MgO-C ⁇ 2 -12H 2 O, (Mg 6 Al 2 (OH) I6 CO 3 ⁇ H 2 O), MgO-Al 2 ⁇ 3 -2Si ⁇ 2 -nH 2 O, aluminium hydroxide/sodium bicarbonate coprecipitates or similar compounds, or other pharmaceutically acceptable pH-buffering compounds, such a the sodium, potassium, calcium, magnesium and aluminium salts of phosphoric, carbonic, citric or other suitable, week, inorganic or organic acids, or suitable organic bases, including
  • the optionally applied separating layer is not essential for the tablets according to the invention. However, the separating layer may improve the chemical stability of the active substance and/or the physical properties of the tablet.
  • enteric coating layers are applied onto the tablet cores or onto the tablet cores covered with separating layer (s) by using a suitable coating technique.
  • the enteric coating layer material may be dispersed or dissolved in either water or in suitable organic solvents and is preferably comprising a polymer.
  • enteric coating layer polymers one or more, separately or in combination, of the following can be used: solutions or dispersions of methacrylic acid copolymers, cellulose acetate phthalate, hydroxypropyl methylcellulose phthalate, hydroxypropyl methylcellulose acetate succinate, polyvinyl acetate phthalate, cellulose acetate trimellitate, carboxymethylethylcellulose, shellac or other suitable enteric coating layer polymer (s).
  • the enteric coating layers may contain pharmaceutically acceptable plasticizers to obtain the desired mechanical properties, such as flexibility and hardness of the enteric coating layers.
  • plasticizers are for the instance, but not restricted to, triacetin, citric acid esters, phthalic acid esters, dibutyl sebacate, dimethyl polysiloxan, cetyl alcohol, stearyl alcohol, polyethylene glycols, propylenglycole, polysorbates or other plasticizers.
  • the amount of plasticizer is optimized for each enteric coating layer formula, in relation to selected enteric coating layer polymer (s), selected plasticizer (s) and the applied amount of said polymer(s), in such a way that the mechanical properties, i.e. flexibility and hardness of the enteric coating layer (s) are adjusted.
  • the amount of plasticizer is usually 10-50 % by weight of the enteric coating layer polymer (s).
  • Additives such as dispersants, colorants, pigments, polymers, anti-tacking agent and antifoaming agents may also be included into the enteric coating layer (s) .
  • Other compounds may be added to increase film thickness and to decrease diffusion of acidic gastric juices into the acid susceptible material.
  • the enteric coating layer (s) constitutes a thickness of about at least 10 ⁇ m, preferably more than 20 ⁇ m.
  • the maximum thickness of the applied enteric coating layer (s) is normally only limited by processing conditions. The invention is in the following further illustrated by means of examples.
  • the amorphous form was indicated by the X-ray powder diffraction pattern and DSC (plain halo effect and glass transition at about 40°C) .
  • esomeprazole arginine was obtained from the above solution by spray drying.
  • Example 1 (ii.) Preparation of esomeprazol arginine (5- methoxy-2- [ (S) - [ (4-methoxy-3, 5-dimethyl-2- pyridinyl) methyl] sulphinyl] -lH-benzimidazole arginine)
  • a drug suspension was prepared using esomeprazole arginine, hydroxypropyl methylcellulose, magnesium carbonate, sodium lauryl sulphate and purified water. Suspension layering of sugar spheres was performed in a fluid bed processor using bottom spray technique (Wurster column) . The spray operation was stopped when the specified amount of bulk liquid had been sprayed.
  • the prepared core material was dried until the loss on drying of the pellets was about 1-1.5 % and covered with a separating layer in a Wurster column with a hydroxypropyl methylcellulose solution containing talc, dibasic sodium phosphate and magnesium stearate .
  • the enteric coating suspension was prepared using methacrylic acid ethyl acrylate copolymer (Eudragit L 30 D-55), triethyl citrate, glyceryl monostearate and Polysorbate 80.
  • the suspension was sprayed onto the pellets covered with separating layer in a fluid bed apparatus. The spray operation was stopped when the specified amount of bulk liquid had been sprayed, and then drying was carried in the Wurster column.
  • the resulting pellets were classified by sieving. Micro- crystalline cellulose and sodium stearyl fumarate were added and the mixture was compressed into tablets using a rotary tableting machine .
  • Esomeprazole arginine, mannitol, hydroxypropyl cellulose, microcrystalline cellulose and magnesium carbonate were premixed in a mixer. By adding an aqueous solution of sodium lauryl sulphate the mass was wet-mixed to a proper consistency. The wet mass was pressed through an extruder and spheronized to pellets. The pellets were dried in a fluid bed dryer until the loss on drying was about 1-1.5 %, and then they were classified by sieving.
  • the prepared core material was covered with a separating layer.
  • Magnesium carbonate was suspended in a hydroxypropyl methyl- cellulose solution and the dispersion was sprayed onto agitated pellets in a Wurster column.
  • the enteric coating layer was applied to the pellets covered with separating layer using an aqueous dispersion of methacrylic acid ethyl acrylate copolymer (Eudragit L 30 D-55) and ethyl acrylate methyl methacrylate copolymer (Eudragit NE 30 D) plasticized with propylenglycole to which a glyceryl monostearate dispersion had been added.
  • the suspension was sprayed onto the pellets covered with the separating layer in a Wurster column until the specified amount of bulk liquid had been sprayed. The drying process was carried out in the same equipment .
  • Additional coating was applied in a Wurster column by spraying a dispersion of hydroxypropyl methylcellulose, microcrystalline cellulose and polyethylene glycol on the enteric-coated pellets.
  • Example 5 The resulting pellets were dried, classified by sieving and compressed into tablets together with microcrystalline cellulose and sodium stearyl fumarate using a rotary tableting machine.
  • Example 5 The resulting pellets were dried, classified by sieving and compressed into tablets together with microcrystalline cellulose and sodium stearyl fumarate using a rotary tableting machine.
  • the esomeprazole arginine layer was added to the beads in a rotor fluidized bed equipment at a batch size of 2.5 kg. Methylcellulose was dissolved in a minimum amount of water, and the solution was slowly sprayed onto the agitating batch of microcrystalline spheres (0.20 - 0.35 mm), while esomeprazole arginine, zinc hydroxide carbonate, mannitol, corn starch and hydroxypropyl cellulose, low substituted, as a powder mixture were intermittently added at a rate such that they adhered to the beads without loss through dusting. When the esomeprazole arginine layer was fully formed, the pellets were dried in an oven at 40 0 C until the loss on drying of the pellets was about 1-1.5 %, and then they were classified by sieving.
  • the prepared core material was covered with a separating layer in a Wurster column. Methylcellulose was dissolved in water, and the zinc hydroxide carbonate was dispersed in the solution. The resulting suspension was sprayed onto the pellets covered with esomeprazole arginine layer.
  • the enteric coating suspension was prepared using methacrylic acid ethyl acrylate copolymer (Eudragit L 30 D-55), polyethylene glycol 6000, talc, titanium dioxide and Polysorbate 80. The suspension was sprayed onto the pellets covered with separating layer in a Wurster column until the specified amount of bulk liquid had been sprayed. The drying process was carried in the same equipment.
  • Example 6 After overcoating the pellets were classified by sieving and compressed into tablets together with microcrystalline cellulose, crospovidone, polyethylene glycol 6000 and magnesium stearate on a rotary tableting machine.
  • Example 6 After overcoating the pellets were classified by sieving and compressed into tablets together with microcrystalline cellulose, crospovidone, polyethylene glycol 6000 and magnesium stearate on a rotary tableting machine.
  • the following powders were mixed together: lactose, esomeprazole arginine, hydroxypropyl cellulose (low degree of substitution), talc and L-arginine. Hydroxypropyl cellulose was dissolved in a sufficient quantity of purified water and used as granulation liquid for the powder mixture. After the granulation, the granules were dried, sieved, magnesium stearate was added and tablets were prepared by compressing the granules using a rotary compression machine.
  • the tablet cores were further coated with a separating layer.
  • the isopropyl alcohol/methylene chloride dispersion of hydroxy- propyl methylcellulose, magnesium hydroxide and talc was sprayed onto the tablets in a suitable coating pan until a desired weight gain was reached. The drying was carried out in the coating pan.
  • Such coated tablets were loaded in a perforated coating pan to be further coated with an enteric layer.
  • An enteric coating suspension was prepared by dispersing hydroxypropyl methylcellulose phthalate, talc, titanium dioxide and diethyl phthalate in the mixture of methanol and methylene chloride. The enteric coating suspension was sprayed simultaneously. The spraying operation was stopped when the specified amount of liquid had been sprayed, and then drying was carried out in the coating pan.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP06841138A 2005-12-22 2006-12-22 Esomeprazol-arginin Withdrawn EP1963306A2 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP06841138A EP1963306A2 (de) 2005-12-22 2006-12-22 Esomeprazol-arginin

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05028252A EP1801110A1 (de) 2005-12-22 2005-12-22 Argininsalz des Esomeprazols
PCT/EP2006/012477 WO2007071444A2 (en) 2005-12-22 2006-12-22 Esomeprazole arginine
EP06841138A EP1963306A2 (de) 2005-12-22 2006-12-22 Esomeprazol-arginin

Publications (1)

Publication Number Publication Date
EP1963306A2 true EP1963306A2 (de) 2008-09-03

Family

ID=36192129

Family Applications (2)

Application Number Title Priority Date Filing Date
EP05028252A Withdrawn EP1801110A1 (de) 2005-12-22 2005-12-22 Argininsalz des Esomeprazols
EP06841138A Withdrawn EP1963306A2 (de) 2005-12-22 2006-12-22 Esomeprazol-arginin

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP05028252A Withdrawn EP1801110A1 (de) 2005-12-22 2005-12-22 Argininsalz des Esomeprazols

Country Status (2)

Country Link
EP (2) EP1801110A1 (de)
WO (1) WO2007071444A2 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102008045339A1 (de) * 2008-09-01 2010-03-04 Stada Arzneimittel Ag Pharmazeutisches Pellet
EP2331084A4 (de) * 2008-10-06 2014-01-22 Jubilant Life Sciences Ltd Pharmazeutische zusammensetzung mit amorphem esomeprazol sowie dosierungsformen davon und verfahren dafür
WO2010097583A1 (en) 2009-02-24 2010-09-02 Cipla Limited Esomeprazole potassium polymorph and its preparation
WO2010148314A2 (en) * 2009-06-19 2010-12-23 Dr. Reddy's Laboratories Ltd. Preparation of esomeprazole and its pharmaceutically acceptable salts
WO2011058569A1 (en) 2009-11-12 2011-05-19 Hetero Research Foundation Process for the resolution of omeprazole

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (sv) 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
EP0012495B1 (de) 1978-12-08 1983-06-22 Beecham Group Plc Pharmazeutische Zusammensetzung enthaltend ein wasserlösliches Salz von Amoxycillin und Polyvinylpyrrolidon, und eine Ampulle die eine Einheitsdosis dieser Zusammensetzung enthält
SE8301182D0 (sv) 1983-03-04 1983-03-04 Haessle Ab Novel compounds
SE9002043D0 (sv) 1990-06-07 1990-06-07 Astra Ab Improved method for synthesis
DE4035455A1 (de) 1990-11-08 1992-05-14 Byk Gulden Lomberg Chem Fab Enantiomerentrennung
SE9301830D0 (sv) 1993-05-28 1993-05-28 Ab Astra New compounds
SE9302396D0 (sv) 1993-07-09 1993-07-09 Ab Astra A novel compound form
SE504459C2 (sv) 1994-07-15 1997-02-17 Astra Ab Förfarande för framställning av substituerade sulfoxider
GB9423970D0 (en) 1994-11-28 1995-01-11 Astra Ab Oxidation
HRP960232A2 (en) 1995-07-03 1998-02-28 Astra Ab A process for the optical purification of compounds
SE508669C2 (sv) 1996-04-26 1998-10-26 Astra Ab Nytt förfarande
SE510666C2 (sv) 1996-12-20 1999-06-14 Astra Ab Nya Kristallmodifikationer
SE510650C2 (sv) 1997-05-30 1999-06-14 Astra Ab Ny förening
SE9704183D0 (sv) 1997-11-14 1997-11-14 Astra Ab New process
WO1999053918A1 (en) 1998-04-20 1999-10-28 Eisai Co., Ltd. Stabilized compositions containing benzimidazole-type compounds
SI20019A (sl) 1998-07-13 2000-02-29 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Izboljšan postopek sinteze 5-metoksi -2-/(4-metoksi-3,5-dimetil-2-piridil)metil/ sulfinil-1H-benzimidazola
US6166213A (en) 1998-08-11 2000-12-26 Merck & Co., Inc. Omeprazole process and compositions thereof
DE69911159T2 (de) 1999-01-06 2004-06-24 Técnimede-Sociedade Técnico-Medicinal, S.A. Cyclodextrin Einschlusskomplexe mit Aminosäuresalzen von Benzimidazolderivaten, deren Herstellung, sowie diese enthaltende pharmazeutische Zusammensetzungen
SE9900274D0 (sv) 1999-01-28 1999-01-28 Astra Ab New compound
CA2290893C (en) 1999-11-16 2007-05-01 Bernard Charles Sherman Magnesium omeprazole
CA2386716C (en) 2002-05-17 2012-07-24 Bernard Charles Sherman Magnesium salt of s-omeprazole
AU2002321204B2 (en) 2001-07-16 2008-05-08 Janssen Pharmaceutica N.V. Improved process for preparing benzimidazole-type compounds
US20030025918A1 (en) 2001-07-16 2003-02-06 August Technology Corp. Confocal 3D inspection system and process
SE0104295D0 (sv) 2001-12-18 2001-12-18 Astrazeneca Ab New process
ES2286408T3 (es) 2002-03-05 2007-12-01 Astrazeneca Ab Sales de alquilamonio de omeprazol e esomeprazol.
US7169793B2 (en) 2002-06-27 2007-01-30 Dr. Reddy's Laboratories Limited Process for preparation of optically pure or optically enriched sulfoxide compounds, including amorphous esomeprazole and salts thereof
EA200500673A1 (ru) 2002-10-22 2005-12-29 Рэнбакси Лабораториз Лимитед Аморфная форма соли эзомепразола, способ ее получения и фармацевтическая композиция на её основе
AR042277A1 (es) 2002-12-06 2005-06-15 Altana Pharma Ag Un procedimiento para la preparacion de sulfinil benzimidazoles opticamente puros
CA2520157A1 (fr) 2003-03-28 2004-10-14 Sidem Pharma Procede de preparation enantioselective de derives de sulfoxydes
CN1842525A (zh) 2003-05-05 2006-10-04 兰贝克赛实验室有限公司 苯并咪唑衍生物的钡盐
WO2004099182A1 (en) 2003-05-05 2004-11-18 Ranbaxy Laboratories Limited Zinc salt of (s)-omeprazole
SE0302381D0 (sv) 2003-09-04 2003-09-04 Astrazeneca Ab New salts I
SE0302382D0 (sv) 2003-09-04 2003-09-04 Astrazeneca Ab New salts II
WO2005054228A1 (en) 2003-12-05 2005-06-16 Hetero Drugs Limited A process for the preparation of substitited pyridinylmethylsulfinyl- benzimidazole enantiomers
DE602004025386D1 (de) 2004-05-28 2010-03-18 Hetero Drugs Ltd Neue stereoselektive synthese von benzimidazolsulfoxiden

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2007071444A2 *

Also Published As

Publication number Publication date
WO2007071444A2 (en) 2007-06-28
WO2007071444A3 (en) 2007-08-09
EP1801110A1 (de) 2007-06-27

Similar Documents

Publication Publication Date Title
CN1138534C (zh) 多单元片剂
EP2398792B1 (de) Zur behandlung von copd geeignetes tosylatsalz eines 5-pyrazolyl-2-pyridonderivats
EP1552833B1 (de) Herstellung eines amorphen, optisch aktiven Isomers von Lansoprazol
EP1678139B1 (de) Montelukast in fester phase
EP2308864A1 (de) Pharmazeutische Zubereitung enhaltend Duloxetin Hydrochlorid
EP2262790B1 (de) Kristall einer benzimidazolverbindung
CN1134667A (zh) 含有质子泵抑制剂的多单元片剂
WO2009088857A1 (en) Crystalline solvated forms of (r) -2- [ [ [3-methyl-4- (2, 2, 2-trifluoroethoxy) -2-pyridinyl] methyl] sulfinyl] -1h-benz imidazole
WO2002044167A1 (en) Process for the crystallization of (r)- or (s)-lansoprazole
EP2303866B1 (de) Kristalline formen von rabeprazol-natrium
WO2008092939A2 (en) Process for the preparation of optically pure omeprazole via salt formation with a chiral amine or treatment with an entiomer converting enzyme and chromatographic separation
KR20080108406A (ko) 술피닐벤즈이미다졸 화합물의 염과 이것의 결정 및비정질체
EP1963306A2 (de) Esomeprazol-arginin
CN115463133A (zh) 一种药物组合物、制剂及其制备方法和应用
US20100183710A1 (en) Omeprazole form b
EP2048144A1 (de) Herstellungsverfahren für optisch reines Omeprazol via Salzbildung mit einem chiralen Amin
WO2011095984A1 (en) A process for the preparation of amorphous esomeprazole
HK40082657B (zh) 一种药物组合物、制剂及其制备方法和应用
WO2006132217A1 (ja) ベンズイミダゾール化合物の塩の結晶
HK1162498B (en) Tosylate salt of a 5-pyrazolyl-2-pyridone derivative, useful in the treatment of copd
SI22447A (sl) Nov postopek za pripravo enantiomerno obogatenega omeprazola

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20080701

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

17Q First examination report despatched

Effective date: 20100615

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20101026